首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Oncologist

Oncologist杂志,由AlphaMed Press出版,于1996年创刊,Monthly,出版语言English,ISSN:1083-7159,E-ISSN:1549-490X。

投稿咨询
Oncologist
Oncologist
Oncologist
SCI SCIE

杂志介绍

JCR分区
Q2
中科院分区
2区
影响因子
4.7
CiteScore
6.8
期刊收录
SCI、SCIE

Oncologist(中文译名:《肿瘤学家》),ISSN:1083-7159,EISSN:1549-490X,是AlphaMed Press出版的国际性学术期刊,创刊于1996年,以Monthly形式稳定发行,2026年总发文量约376篇。该刊采用非OA开放访问,学科归属为医学 - 肿瘤学。该刊是医学、肿瘤学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达4.7,2025年期刊CiteScore为6.8,2025年期刊自引率约2.1%,在中科院期刊分区体系中位列医学大类2区TOP 期刊,在所属学科领域具备高学术影响力与国际认可度。Oncologist长期聚焦医学、肿瘤学及相关产业的技术应用前沿,平均审稿周期一般,3-8周,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、肿瘤学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,USACHINA MAINLAND、Italy、France、Spain、Japan、GERMANY (FED REP GER)等为核心发文国家与地区;HARVARD UNIVERSITYMASSACHUSETTS GENERAL HOSPITAL、UNIVERSITY OF TEXAS SYSTEM、DANA-FARBER CANCER INSTITUTE、UNIVERSITY OF CALIFORNIA SYSTEM、MEMORIAL SLOAN KETTERING CANCER CENTER、MAYO CLINIC等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
ONCOLOGY 肿瘤学
2区
是 否

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
ONCOLOGY 肿瘤学
2区
否 否

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
ONCOLOGY 肿瘤学
2区
是 否

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q2 97 / 333

71

学科:ONCOLOGY SCIE Q2 102 / 333

69.52

2024-2025年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q2 89 / 328

73

学科:ONCOLOGY SCIE Q2 87 / 328

73.63


中国学者近期发文

1
Lenvatinib combined with immune checkpoint inhibitors for unresectable, recurrent, or metastatic hepatocellular carcinoma: a real-world stud

Author:Kong, Huifang; Chen, Yan; Li, Hong; Wang, Di; Chang, Xiujuan; Zeng, Zhen; Zhang, Wei

Journal: ONCOLOGIST. 2026; Vol. 31, Issue 5, pp. -. DOI: 10.1093/oncolo/oyag097

2
Dynamic cytogenetic evolution in multiple myeloma: prognostic implications from diagnosis to first relaps

Author:Chen, Qi; Tian, Tian; Shi, Yu; Shen, Xuxing; Qiu, Hairong; Jin, Yuanyuan; Chen, Lijuan; Guo, Rui

Journal: ONCOLOGIST. 2026; Vol. 31, Issue 5, pp. -. DOI: 10.1093/oncolo/oyag105

3
Low opinion of generic oral anticancer drugs: an unacknowledged factor resulting in medication waste in Chin

Author:Wang, Yan; Song, Hongwei; Cao, Jinming; Chen, Zhicong; Xu, Feng

Journal: ONCOLOGIST. 2026; Vol. 31, Issue 5, pp. -. DOI: 10.1093/oncolo/oyag057

4
Association of IDH1 mutations with survival and recurrence in resected intrahepatic cholangiocarcinoma received or not received adjuvant chemotherap

Author:Wang, Pengcheng; Li, Ning; Ye, Yuhang; Pu, Jing; Sun, Rongqi; Luo, Chubin; Hu, Zhiqiang; Zhou, Zhengjun; Li, Jia; Zou, Jixue; Fan, Jia; Zhou, Jian; Zhou, Shaolai

Journal: ONCOLOGIST. 2026; Vol. 31, Issue 5, pp. -. DOI: 10.1093/oncolo/oyag124

5
Treatment strategies for small cell carcinoma of the esophagus: comparative analysis of multimodal regimens in two independent real-world cohort

Author:Yin, Xiaolei; Li, Xiaopeng; Mi, Lili; Hou, Jiaojiao; Yin, Fei

Journal: ONCOLOGIST. 2026; Vol. 31, Issue 5, pp. -. DOI: 10.1093/oncolo/oyag115

6
The efficacy of sequential radiotherapy after the combination of TACE with lenvatinib and anti-PD-1 antibodies for unresectable HC

Author:Ou, Xiangye; Li, Jinhai; Pan, Rongjian; Liu, Deyi; Wu, Jiayi; Liang, Dong; Li, Yinan; Zeng, Zhenxin; Li, Han; Zhang, Yuxuan; Wu, Junyi; Yan, Maolin

Journal: ONCOLOGIST. 2026; Vol. 31, Issue 5, pp. -. DOI: 10.1093/oncolo/oyag138

7
Predictive modeling of treatment-related thyroid dysfunction and prognostic implication in advanced nasopharyngeal carcinoma with PD-1 inhibitor

Author:Hu, Yubin; Hong, Xinyi; Li, Yi; Zhang, Honghong; Warsi, Mohammad Abidullah; Chen, Ronghui; Lin, Chaoying; Ou, Peidong; Lin, Cuibo; Qiu, Sufang

Journal: ONCOLOGIST. 2026; Vol. 31, Issue 4, pp. -. DOI: 10.1093/oncolo/oyag066

8
Construction of a predictive model based on the risk of relapse after cytarabine consolidation therapy in acute myeloid leukemia patient

Author:Ji, Min; Hao, Yiping; Li, Wei; Zhou, Ying; Jia, Ruinan; Li, Wei; Jin, Shumin; Dai, Min; Chang, Mengyuan; Feng, Lei; Liu, Tingting; Zhang, Di; Ji, Chunyan; Ye, Jingjing

Journal: ONCOLOGIST. 2026; Vol. 31, Issue 4, pp. -. DOI: 10.1093/oncolo/oyag088

9
Atezolizumab and motixafortide, cobimetinib or simlukafusp alfa in pretreated advanced pancreatic cancer: phase I/IIb MORPHEUS-PDAC umbrella stud

Author:Manji, Gulam A.; Chung, Vincent; Oh, Do-Youn; Lacy, Jill; Lopez, Charles D.; Ponz-Sarvise, Mariano; Macarulla, Teresa; Thomas, Roby; George, Ben; Alistar, Angela; Siveke, Jens T.; Xu, Yun; Lau, Janet; Cha, Edward; Kim, Kyu-Pyo; O'Reilly, Eileen M

Journal: ONCOLOGIST. 2026; Vol. 31, Issue 4, pp. -. DOI: 10.1093/oncolo/oyag023

10
A prospective post-marketing observational study of abemaciclib in patients with HR+, HER2-breast cancer in Chin

Author:Ouyang, Quchang; Yuan, Peng; Liu, Jianxia; Teng, Yuee; Li, Zhihua; Ji, Xuening; Liu, Lina; Wang, Mopei; Zou, Liqun; Xu, Ling; Yang, Suisheng; Zhu, Zhenxin; Yang, Liu; Li, Jinnan; Liu, Qiang

Journal: ONCOLOGIST. 2026; Vol. 31, Issue 4, pp. -. DOI: 10.1093/oncolo/oyag013


在线咨询

Oncologist

国际简称:ONCOLOGIST参考译名:肿瘤学家

年发文量:376 CiteScore:6.8 是否预警:否 Gold OA文章占比:99.80% 研究类文章占比:85.64%

杂志社联系方式:ALPHAMED PRESS, 318 BLACKWELL ST, STE 260, DURHAM, USA, NC, 27701-2884

Oncologist